Cancer biologist trained in rigorous hypothesis-driven research, with over 12 years of experience spanning academic discovery at Johns Hopkins Medicine and industry-based translational research. My work has focused on understanding tumor biology across multiple contexts, including immuno-oncology, cancer stem cell biology, and hypoxia signaling (HIF-1), with an emphasis on translating biological insights into experimentally testable systems. In recent years, I have transitioned into industry, where I work at the interface of experimental execution and data interpretation in ex vivo oncology models. This includes evaluating therapeutic responses in complex systems and addressing challenges such as model variability, assay limitations, and non-linear pharmacological behavior. I am particularly interested in how experimental design and model context influence the interpretation of drug response, and in developing practical frameworks that improve the reliability and decision value of preclinical data. With a foundation in both academic research and industry applications, I bring a balanced perspective that integrates biological depth, technical rigor, and translational thinking to support cancer therapeutic development.